First Tracks Biotherapeutics' ANB033 shows significant benefits in Phase 1b celiac disease trial

First Tracks Biotherapeutics released topline results from Cohort 1 of its Phase 1b gluten-challenge trial of ANB033 in celiac disease, showing statistically significant histologic and symptom benefits. ANB033 showed a +0.49 placebo-adjusted change in Vh:Cd ratio (p=0.009) and improved IEL density. The stock jumped more than 13% following the announcement.

Detected & updated continuously · Source: Nebula